Biognosys Completes Series G Financing Round to Accelerate its Expansion into Clinical Trials Market

Biognosys closes Series G round with new and existing investors to accelerate implementation of discovery proteomics in clinical trials.

(PresseBox) ( Schlieren, )
Biognosys, a Swiss proteomics company, continues realizing its ambition to enable clinical researchers to directly measure and quantify thousands of proteins from patient tissues in clinical trials by offering its next-generation label-free proteomics technology. To accelerate this development, the company has raised new funds in Series G financing round.

Biognosys provides proteomics research services to innovative pharma and biotech firms. They use the company’s technology in their pre-clinical research, providing deep and precise protein expression profiling for the development of biomarkers and analysis of mode of action. As demand for the use of these services in the clinical phase is growing, the new financing round will help the company to further scale up its operations and start serving clients’ drug development projects in the clinical phases.

Dr. Oliver Rinner, Founder and CEO of Biognosys, says: “We are striving to provide the deepest and most precise proteomics data to our clients. We are very excited with the perspective to be pioneers in bringing discovery proteomics to clinical trials and provide our advanced data analysis services at a much larger scale.”

The financing round includes a new industrial investor, in addition to existing institutional and private shareholders. The funds will be invested into building a new GCP-certified facility in Switzerland, increasing current operational capacity as well as enhancing the company’s sales force, further expanding its commercial presence in the US (both East and West Coast), Europe, and Asia.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an service@pressebox.de.